Valuation: Evotec SE

Market Cap 61Cr 71Cr 58Cr 52Cr 98Cr 6.78TCr 100.04Cr 674.42Cr 263.69Cr 3.4TCr 266.26Cr 260.48Cr 11TCr P/E 2026 *
-2.94x
P/E 2027 * -8.01x
Enterprise Value 76Cr 87Cr 71Cr 65Cr 121.37Cr 8.36TCr 123.37Cr 831.7Cr 325.19Cr 4.19TCr 328.36Cr 321.23Cr 14TCr EV / Sales 2026 *
1.26x
EV / Sales 2027 * 1.08x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
1 day-6.90%
1 week+1.25%
Current month+1.89%
1 month+4.52%
3 months-26.36%
6 months-44.90%
Current year-38.64%
1 week 1.62
Extreme 1.62
1.88
1 month 1.56
Extreme 1.56
2.02
Current year 1.55
Extreme 1.55
3.2
1 year 1.55
Extreme 1.55
3.54
3 years 1.55
Extreme 1.55
11
5 years 1.55
Extreme 1.55
85.5
10 years 1.55
Extreme 1.55
85.5
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO - 01/05/2026
Chief Operating Officer - 01/05/2026
Director TitleAgeSince
Director/Board Member 58 19/06/2019
Director/Board Member 64 01/06/2021
Director/Board Member 59 10/06/2024
Change 5-day change 1-year change 3-year change Capi.($)
-6.90%+1.25% - - 71Cr
-1.78%-1.68%+1.48%+17.26% 4.84TCr
+0.85%-0.70%+460.88%+581.30% 4.37TCr
-2.40%-0.23%+8.13%+80.67% 3.95TCr
-2.01%-0.85%+23.85%+9.97% 3.9TCr
-0.50%+0.85%+20.60%+58.18% 3.26TCr
+0.38%-3.23% - - 1.63TCr
-0.59%-2.06%+26.35%+126.36% 1.61TCr
+0.49%+0.92%+4.11%+26.37% 1.42TCr
-0.43%+4.70%+78.74%+38.66% 1.34TCr
Average -1.29%-0.04%+78.02%+117.35% 2.92TCr
Weighted average by Cap. -0.93%-0.11%+95.83%+140.26%

Financials

2026 *2027 *
Net sales 60Cr 69Cr 56Cr 51Cr 96Cr 6.64TCr 98Cr 660.27Cr 258.16Cr 3.32TCr 260.68Cr 255.02Cr 11TCr 72Cr 83Cr 68Cr 61Cr 115.55Cr 7.96TCr 117.46Cr 791.86Cr 309.61Cr 3.99TCr 312.63Cr 305.85Cr 13TCr
Net income -24Cr -27Cr -22Cr -20Cr -38Cr -2.61TCr -39Cr -259.67Cr -101.53Cr -1.31TCr -102.52Cr -100.29Cr -4.35TCr -6.04Cr -6.99Cr -5.67Cr -5.16Cr -9.7Cr -668.39Cr -9.86Cr -66Cr -26Cr -334.71Cr -26Cr -26Cr -1.11TCr
Net Debt 14Cr 17Cr 13Cr 12Cr 23Cr 1.58TCr 23Cr 157.28Cr 61Cr 791.98Cr 62Cr 61Cr 2.63TCr 16Cr 19Cr 15Cr 14Cr 26Cr 1.8TCr 26Cr 178.55Cr 70Cr 899.07Cr 70Cr 69Cr 2.99TCr
Logo Evotec SE
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
4,461
Date Price Change
14/26/14 €1.620 -6.90%
13/26/13 €1.740 -7.45%
12/26/12 €1.880 +9.94%
11/26/11 €1.710 -7.07%
10/26/10 €1.840 +15.00%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
3.446EUR
Average target price
4.300EUR
Spread / Average Target
+24.78%

Quarterly revenue - Rate of surprise